Texas Children's Hospital Center for Vaccine Development

Now entering its third decade, the Texas Children’s Hospital Center for Vaccine Development is internationally recognized for its leadership in advancing vaccines for poverty-related neglected and emerging infectious diseases (NTDs).

The Center is committed to developing and testing affordable, effective vaccines and immunotherapies for diseases that disproportionately affect underserved populations. Its dual mission is to create and evaluate these interventions while also building both local and global capacity for vaccine development.

Key Achievements Include:

• Developed a COVID-19 vaccine administered over 100 million times in India and Indonesia.
• Advanced vaccine candidates for emerging coronaviruses, including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
• Created the first vaccine for human hookworm infection, currently in clinical trials.
• Developed the first vaccine for intestinal schistosomiasis, now in clinical trials.
• Pioneered the first vaccine for Chagas disease, also in clinical trials.
• Established a portfolio of early-stage vaccines targeting other major parasitic diseases, including soil-transmitted helminths, onchocerciasis, and leishmaniasis.